Effective multiple sclerosis management through improved patient assessment.
Multiple sclerosis (MS) is a complex disease with a wide range of clinical manifestations. Current disease-modifying drugs (DMDs) are effective, but they are associated with effects that may negatively influence treatment compliance. A recent nursing advisory board of MS nurse experts from the Midwest discussed management approaches that can enhance DMD compliance and improve patient satisfaction and quality of life. One such approach is the use of patient questionnaires as tools to assess signs and symptoms of MS and treatment-related adverse effects. Information gained in this manner is beneficial to MS healthcare professionals as well as patients and has the potential to improve treatment compliance and outcomes and disease management.
Ross
Amy Perrin
AP
Loyola University, Chicago, IL, USA. Aperrin@lumc.edu
Hackbarth
Natalie
N
Rohl
Christine
C
Whitmyre
Kristi
K
D000203:Activities of Daily Living; D003937:Diagnosis, Differential; D019468:Disease Management; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control* / Q000523:psychology; D020380:Needs Assessment; D009730:Nursing Assessment / Q000458:organization & administration*; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D010455:Peptides / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011788:Quality of Life; D012648:Self Care; D012647:Self-Assessment; D011795:Surveys and Questionnaires
D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone